Understanding Clinical Inertia in Atopic Dermatitis: A Mixed-Methods Study of Barriers to Treatment Escalation

Area of Science:

• Dermatology
• Clinical Research
• Healthcare Management

Background:

• Effective therapies exist for moderate-to-severe atopic dermatitis (AD), yet timely treatment escalation is often lacking.
• Clinical inertia, a phenomenon seen in chronic diseases, is understudied in dermatology, particularly for AD.
• This study aimed to quantify clinical inertia in AD and identify associated patient, physician, and system-level barriers.

Purpose of the Study:

• To quantify the extent of clinical inertia in moderate-to-severe atopic dermatitis (AD).
• To identify patient-, physician-, and system-level barriers contributing to delayed treatment escalation in AD.
• To inform strategies for improving timely access to advanced therapies for AD patients.

Main Methods:

• A cross-sectional mixed-methods study was conducted at a tertiary dermatology center.
• Forty adults with moderate-to-severe AD completed validated questionnaires assessing disease severity, quality of life, treatment satisfaction, and medication beliefs.
• Semi-structured interviews with 20 patients were analyzed using thematic content analysis to explore barriers.

Main Results:

• 30% of patients with moderate-to-severe AD had not received systemic therapy.
• Patient-reported barriers included low treatment expectations, fear of side effects, and acceptance of chronic symptoms.
• Thematic analysis revealed five key barriers: therapeutic nihilism, limited specialist access, fragmented communication, physician-level inertia, and system inefficiencies.

Conclusions:

• Clinical inertia in AD is multifactorial, influenced by patient perceptions, communication, and healthcare structures.
• Recommendations include structured shared decision-making, treat-to-target management with regular monitoring, and system-level improvements like clear referral pathways and streamlined approvals.
• Addressing clinical inertia is crucial for timely and equitable care as AD treatment options evolve.